The lawsuit, brought by a hedge fund and an individual stockholder, accuses the board of rushing to accept the $8.52-per-share offer from Atlas affiliates Nov. 3—and shield it from competing bids with a suite of defensive measures, including a poison pill—even as Chatham was publicly offering more.
“The board’s decision to maintain the poison pill to ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.